Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) just unveiled an announcement.
Cosmo Pharmaceuticals announced that potential US tariffs on Swiss pharmaceutical companies will not impact its operations, as it does not export from Switzerland to the US and has long-term global contracts. The company remains optimistic about its growth trajectory, bolstered by strong fundamentals and increased EBITDA, and continues to deliver stable results to shareholders.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs and manufactures advanced medical solutions, aiming to improve healthcare standards globally. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with additional offices in the USA and Italy.
Average Trading Volume: 25,014
Technical Sentiment Signal: Sell
Current Market Cap: CHF936.2M
Learn more about COPN stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “If Safety is Your Number One Goal, Don’t Buy the Roadster”: Tesla Stock (NASDAQ:TSLA) Sinks as the Roadster’s Priorities Emerge
- “…No Expectations of Receiving Anything…” Comcast Stock (NASDAQ:CMCSA) Gains as it Tackles Misconduct Allegations
- Home Depot Stock (NYSE:HD) Slips Despite New AI-Driven Shopping Plan